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Epidertnal growth factor (EGF) dose-dependently enhanced the induction of tyrosine aminotransferase nd 
tryptophan oxygenase by glucocorticoids in primary cultures of adult rat hepatocytes without itself having 
any effect on these nzymes in the absence of glucocorticoids. The amplifications were observed even with 
dexamethasone at high concentrations (lti M-lo-’ M) that had a maximal effect. EGF had no effect on 
induction of tyrosine aminotransferase by glucagon or BtzcAMP. The effect of EGF was also observed in 
adrenal-ectomized and submaxillar gland-ectomized rats. These results suggest hat EGF is an endogenous 
amplifier of the action of glucocorticoids. 
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1. INTRODUCTION 
The activities of tyrosine aminotransferase (EC 
2.6.1 S) (TAT) and tryptophan 2,3-dioxygenase 
(EC 1.13.11.11) (TO) are known to be regulated by 
glucocorticoids [1,2], insulin [3] and glucagon [3]. 
Recently, we found several compounds that 
specifically amplified the induction of TAT by 
glucocorticoids without themselves having any 
glucocorticoid action and named these compounds 
‘glucocorticoid action biomodulators’. Several of 
these compounds, such as diacylglycerol and 12-0- 
tetradecanoylphorbol 13-acetate, are activators of 
protein kinase C [4,5]. 
In order to find endogenous glucocorticoid ac- 
Correspondence address: N. Katunuma, Division of En- 
zyme Chemistry, The Institute for Enzyme Research, 
The University of Tokushima, Tokushima 770, Japan 
Abbreviations: TAT, tyrosine aminotransferase; TO, 
tryptophan 2,3dioxygenase; EGF, epidermal growth 
factor 
tion biomodulators, we examined the effects of a 
number of polypeptide growth factors, such as 
EGF, fibroblast growth factor, platelet-derived 
growth factor and 7S-nerve growth factor, on in- 
duction of TAT and/or TO by glucocorticoids in 
primary cultures of adult rat hepatocytes and in 
adrenal-ectomized plus submaxillar gland- 
ectomized rats. Here we show that EGF specifical- 
ly amplified the induction of liver enzymes by 
glucocorticoids in vitro and in vivo. 
2. MATERIALS AND METHODS 
2.1. Materials 
Male Wistar strain rats, weighing 180-200 g 
were used. Dexamethasone sodium phosphate was 
obtained from Merck. Glucagon and BtzcAMP 
were from Sigma. EGF (mouse) from Toyobo, 
platelet-derived growth factor (human) and 
fibroblast growth factor (bovine) from Col- 
laborative Research and 7S-nerve growth factor 
(mouse) from Wako. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 223 
Volume 223, number 2 FEBS LETTERS November 1987 
2.2. Assay of biological activity 3. RESULTS AND DISCUSSION 
The biological activities of polypeptide growth 
factors in vitro were measured in primary cultures 
of adult rat hepatocytes as reported [5,6]. Isolated 
hepatocytes were suspended at a density of 5 x 10’ 
cells/ml in Williams medium E containing 10% 
calf serum, 10m6 M dexamethasone and 10e7 M in- 
sulin in lo-cm dishes at 37°C under 5% CO2 in air. 
After 36 h, the medium was replaced by hormone- 
free medium containing 10% calf serum. One-day 
cultures were washed twice with serum-free 
medium and then dexamethasone in saline, 
Bt2cAMP in saline, or glucagon in dimethyl sulfox- 
ide and/or each polypeptide growth factor in 
saline was added to the cultures in serum-free 
medium for assay of TAT activity. For assay of 
TO activity, 2.5 mM tryptophan was added in 
serum-free medium. The final concentration of 
dimethyl sulfoxide did not exceed 0.05%. At the 
indicated times, the hepatocytes were washed three 
times with ice-cold Tyrode buffer but without 
divalent cations, harvested with a rubber 
policeman in 2.5 ml of homogenization buffer 
(0.25 M sucrose containing 0.05 M potassium 
phosphate buffer, pH 7.5, 1 mM 2-oxoglutarate 
and 48 /IM pyridoxal phosphate) for the assay of 
TAT, or in 2.5 ml of homogenization buffer 
(20 mM potassium phosphate buffer, pH 7.0, con- 
taining 2.5 mM tryptophan and 2pM meth- 
ohemoglobin) for the assay of TO, and then 
sonicated for 10 s. The sonicate was used for the 
TO assay or was centrifuged at 100500 x g for 
30 min to obtain the supernatant, which was used 
for the TAT assay. The biological activity of EGF 
in adrenal-ectomized plus submaxillar gland- 
ectomized rats was determined by measuring its 
amplification of the induction of TAT in liver by 
dexamethasone as reported [4,5]. 
3.1. Effects of polypeptide growth factors on 
induction of TAT and TO in vitro 
The effects of polypeptide growth factors on the 
induction of TAT and TO by dexamethasone were 
studied in primary cultures of adult rat 
hepatocytes. When dexamethasone (10d7 M) was 
added to the medium, the specific activity of TAT 
increased rapidly to a plateau after incubation for 
4-8 h and then remained constant unless the dex- 
amethasone was removed. When hepatocytes were 
incubated with polypeptide growth factors plus 
dexamethasone (10e7 M) for 8 h, TAT induction 
was markedly amplified by EGF but not by the 
other polypeptide growth factors tested, such as 
fibroblast growth factor, 7S-nerve growth factor 
and platelet-derived growth factor, as shown in 
table 1. In the absence of dexamethasone, these 
polypeptide growth factors including EGF had no 
effect on TAT. EGF amplified not only TAT in- 
duction but also TO induction by dexamethasone. 
The specific activity of TO was enhanced by EGF, 
increasing to a plateau after incubation for 
lo-14 h and then remaining constant for 24 h in 
Table 1 
Effects of polypeptide growth factors on induction of 
TAT by dexamethasone ( 10e7 M) in primary cultures of 
hepatocytes 
Treatment 
(ng/mf) 
Specific activity 
of TAT 
(mU/mg 
protein) 
2.3. Enzyme and protein assays 
TAT activities in the liver homogenate and the 
supernatant of hepatocytes were measured by the 
methods of Rosen et al. [7] and Granner and 
Tomkins [8], respectively. TO activity was deter- 
mined by the method of Seglen and Jervell191. The 
protein concentrations of the cytosolic fractions 
used for the assay of TAT activity and of sonicates 
used for the assay of TO activity were determined 
by the methods of Lowry et al. [lo] and Bradford 
[ 111, respectively. 
None 12.1 f 1.4 
EGF (20) 12.3 it: 1.1 
Platelet-derived growth factor (5) 12.1 f 1.8 
Fibroblast growth factor (20) 12.3 + 1.2 
7S-Nerve growth factor (20) 11.8 + 1.3 
Dexamethasone 52.6 + 4.1 
Dexamethasone + EGF (20) 153.4 f 6.8 
Dexamethasone + platelet-derived 
growth factor (5) 52.9 + 2.4 
Dexamethasone + fibroblast growth 
factor (20) 52.4 f 3.0 
Dexamethasone + 7S-nerve growth 
factor (20) 51.8 + 3.4 
Experimental conditions are described in section 2. 
Values are means + SD for four dishes 
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Fig.1. Dose-response curves of EGF for amplifications 
of TAT and TO induction in rat hepatocytes. TAT 
activities at the indicated concentrations of EGF with 
(0) or without (0) 10m7 M dexamethasone were 
measured after 8 h, and TO activities at the indicated 
concentrations of EGF with (A) or without (A) lo-* M 
dexamethasone w re measured after 20 h. Values are 
means from three dishes. Bars indicate SD values. 
I., I I I I 
0 10-8 qo-’ lo- 10-5 
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the presence of 2.5 mM tryptophan (not shown). 
TAT and TO were not activated directly by addi- 
tion of EGF in vitro (not shown). 
The effects of EGF on TAT and TO induction 
by dexamethasone were concentration-dependent, 
as shown in fig. 1. EGF. was effective at concentra- 
tions of above 2 ng/ml and was maximally effec- 
tive at 10-20 ng/ml. The amplifications of 
induction of TAT and TO induced by EGF 
(10 ng/ml) were reproducible, but the extents of 
the amplifications were variable: 2-3-fold 
amplification of TAT induction and 1.2-1.6-fold 
amplification of TO induction were observed. The 
effects of EGF on the induction of TAT and TO 
were studied as a function of the concentration of 
dexamethasone. As shown in fig.2, EGF 
significantly amplified the induction of TAT 
(fig.2A) and TO (fig.2B) not only by low concen- 
trations of dexamethasone (10m8 M-10-’ M) but 
also by higher concentrations of dexamethasone 
(10e6 M-10-’ M) that had a maximal effect. 
These modes of amplification show that EGF is a 
‘glucocorticoid potency amplifier’ [4], like 
diacylglycerol [4] and 12-0-tetradecanoylphorbol 
13-acetate [5]. Recent studies have shown that 
EGF in A-43 1 cells rapidly generates 
Dexamethasonebl) 
Fig.2. Effect of EGF on the induction of TAT (A) and TO (B) as a function of the dose of dexamethasone in rat 
hepatocytes. In A, TAT activities at the indicated concentrations of dexamethasone with (0) or without (0) EGF 
(10 ng/ml) were measured after 8 h. In B, TO activities at the indicated concentrations of dexamethasone with (0) or 
without (0) EGF (10 r&ml) were measured after 20 h. Values are means for three dishes. Bars indicate SD values. 
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Table 2 
Effects of EGF on induction of TAT by dexamethasone 
in adrenal-ectomized plus submaxillar gland-ectomized 
rats 
Treatment Adrenal-ectomy + sub- 
(dose/100 g body wt) maxillar gland-ectomy 
Specific activity of 
TAT (mU/mg 
protein) 
None 
EGF (5 pg) 
Dexamethasone (2 ng) 
Dexamethasone (2 ng) + 
EGF (5 pg) 
8.1 f 1.5 
7.9 + 1.8 
14.8 f 2.3 
24.2 f 3.0 
EGF and/or dexamethasone in saline was injected 
intraperitoneally and the rats were killed by cervical 
dislocation 5 h later. The livers were homogenized in 
6 vol. of homogenization buffer and TAT activity in the 
homogenate was measured as described in section 2. 
Values are means k SD for 12 rats 
diacylglycerol, resulting from the degradation of 
phosphoinositide, and that the diacylglycerol may 
activate protein kinase C [12]. 
TAT is known to be induced not only by 
glucocorticoids but also by glucagon and BtzcAMP 
in vivo [3] and in vitro [13]. But EGF (2-20 ng/ml) 
had no effect on the induction of TAT by glucagon 
(10-r’ M-10m6 M) or BtzcAMP (10m6 M-10m3 M) 
during incubation for 4 h (not shown). Thus, the 
effect of EGF on TAT induction is apparently 
specific for glucocorticoids. 
3.2. Effects of EGF on induction of TA T in vivo 
In adrenal-ectomized plus submaxillar gland- 
ectomized rats, EGF (5 pg/lOO g body wt) 
amplified TAT induction by dexamethasone 
(2 pg/lOO g body wt) but it had no effect on the en- 
zyme activity in the absence of dexamethasone, as 
shown in table 2. These results show that EGF 
from the submaxillar gland may be an endogenous 
glucocorticoid potency amplifier and may regulate 
glucocorticoid actions. The extent of the 
amplification in vivo was lower than that observed 
in vitro. One possible explanation for this was that 
endogenous EGF was not completely removed by 
LETTERS November 1987 
submaxillar gland-ectomy, because low concentra- 
tions of EGF may be formed in other tissues, such 
as the kidney [14], brain [15] and intestine [la]. 
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